Home Drug Codes J Codes J0222 · ONPATTRO
Updated July 1st, 2026

ONPATTRO J Code: J0222

Injection, patisiran, 0.1 mg

Login to unlock all benchmarks

Q4 2026 Medicare Payment Limit for J0222, effective October 1, 2026: $101.181 per HCPCS billing unit, up 0.2% from $101.026. From CMS's final file.

?
Medicare Payment Limit ?
$101.026
/ HCPCS billing unit · Q3 2026
APC Payment Limit ?
$101.026
/ HCPCS billing unit · APC 9180
ASP ?
$•••.••
Login to view
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
1
View NDC crosswalk →

Drug & Product Overview

HCPCS Descriptor Injection, patisiran, 0.1 mg
HCPCS Added Date October 1, 2019
Manufacturer Alnylam Pharmaceuticals
Route of Administration Intravenous
Generic Status Single-Source; Branded
Dosage Type Single-Dose
Dosage Form Injection, Lipid Complex

About ONPATTRO

Onpattro is a medication aligned to the HCPCS J Code: J0222 for billing, pricing, and reimbursement purposes in the United States. This Genetic Disorder medication is administered via the intravenous route and manufactured by Alnylam Pharmaceuticals.

According to CMS Drug Use Information: This medication is used to treat nerve problems due to a certain inherited condition (transthyretin-mediated amyloidosis). This condition causes a protein that your body normally makes (transthyretin-TTR), to change shape and build up in different parts of your body, which can affect the nerves, heart, and stomach/intestines. This medication works by decreasing the buildup of TTR in your body.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code Drug Manufacturer Billing Units / Pkg Package Size
71336-1000-01 Onpattro Alnylam Pharmaceuticals, Inc. 100 10 MG / 5 ML
Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

ONPATTRO Pricing & Reimbursement

J0222 Private Payer Reimbursement
$99.93 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →
UnitedHealthcare, BlueCross BlueShield, Aetna, Cigna

Historical Graphing and Billing Calculator

per HCPCS unit
As of Q3 2026

ONPATTRO Claims Performance

Claims from Jan 2026 – Aug 2026
Claim Denial Rate 59.79%
Avg. Days to File 6.3days
Avg. Days to Pay 18.3days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J0222 claims analytics on FocalPoint →
OnPoint Oncology

ONPATTRO CPT Administration Codes

The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.

CPT Code Description
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)
JW / JZ modifiers apply

CMS has identified Onpattro (J0222) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

ONPATTRO Medically Unlikely Edits (MUE)

The most billing units of J0222 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 0.1 mg.

Practitioner Office & Hospital Outpatient
300 units / day
= 30 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

mg Enter a dose to see how many billing units it is and whether it is under the limit.

ONPATTRO Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

polyneuropathy of hereditary transthyretin-mediated amyloidosis
Drug Class
Decreased RNA Integrity [PE]Increased Protein Breakdown [PE]RNASmall Interfering [CS]Small Interfering RNA [EPC]Transthyretin-directed RNA Interaction [EPC]

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.

Frequently Asked Questions

Is there an available Onpattro billing and coding guide?
Billing and coding information for ONPATTRO can be found through Alnylam Pharmaceuticals, Inc.. Visit Here →
Are there any available Onpattro patient assistance programs?
ONPATTRO patient assistance information can be found through Alnylam Pharmaceuticals, Inc.. Visit Here →
Where can I find Onpattro prescribing information?
ONPATTRO prescribing information can be found at the link below: Visit Here →
Where can I find Onpattro side effect information?
Our team has not yet identified a source of side effects information for ONPATTRO. Please check back in a few weeks.
Does billing ONPATTRO require JZ/JW wastage modifiers?
CMS has identified ONPATTRO(J0222) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.